Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nerve growth factor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    27 result(s) found for: Nerve growth factor. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2020-005264-60 Sponsor Protocol Number: CHF6467-OPG Start Date*: 2021-11-26
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Safety and Efficacy of multiple doses of the PAINLESS Nerve Growth Factor CHF6467 in subjects with Optic Pathway Glioma (OPG). A randomized clinical trial (RCT)
    Medical condition: Optic pathway glioma - optic neuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073338 Optic glioma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-001438-29 Sponsor Protocol Number: 427/08 Start Date*: 2008-05-15
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: NGF for visual blindness in patient affected by glioma
    Medical condition: gloma with visual blindness
    Disease: Version SOC Term Classification Code Term Level
    9.1 10030935 Optic nerve glioma LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003030-14 Sponsor Protocol Number: 758/11 Start Date*: 2012-09-03
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Nerve Growth Factor (NGF) eye drop administration as visual rescue treatment in visual loss-associated optic gliomas.
    Medical condition: Glioma
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030953 Optic tract glioma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005215-17 Sponsor Protocol Number: 905-EC-007 Start Date*: 2009-09-14
    Sponsor Name:Astellas Pharma Europe Limited
    Full Title: A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and urinary Nerve Growth Factor in Female Subjects with Overactive Bladder and a Diagnosis of Detrusor O...
    Medical condition: Overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    12.0 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) ES (Completed) HU (Completed) CZ (Completed) DE (Completed) AT (Completed) SE (Completed) IT (Completed) SK (Completed) GB (Completed) BG (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004271-12 Sponsor Protocol Number: NGF0213 Start Date*: 2014-01-17
    Sponsor Name:Dompé s.p.a
    Full Title: An open-label study evaluating safety and efficacy of recombinant human nerve growth factor (rhNGF) eye drops at different doses in patients with Dry Eye
    Medical condition: Dry Eye syndrome is caused by either decreased tear production or increased tear film evaporation. Dry eye is a chronic inflammatory condition of the ocular surface with severe symptoms and visual ...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10013777 Dry eye syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002527-15 Sponsor Protocol Number: NGF0212 Start Date*: 2013-03-01
    Sponsor Name:Dompé farmaceutici s.p.a
    Full Title: Study Brand Name : REPARO Study full title: An 8-week phase I/II, multicenter, randomized, double-masked, vehicle controlled parallel group study with a 48 or 56 week follow-up period to evaluat...
    Medical condition: Adult patients diagnosed with unilateral stage 2 (persistent epithelial defect) and stage 3 (corneal ulcer) NK refractory to one or more conventional non-surgical treatments. Patients with Controla...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004853 10032064 Other forms of keratitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) PT (Completed) HU (Completed) ES (Completed) PL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002282-35 Sponsor Protocol Number: rh-NGF Start Date*: 2020-05-13
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Nerve growth factor in pediatric severe traumatic brain injury : translational and clinical studies on a candidate biomarker and therapeutic drug
    Medical condition: Persistent unresponsive wakefulness syndrome (UWS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004863 10049615 Late effects of head trauma LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002435-18 Sponsor Protocol Number: Diclometh-2015 Start Date*: 2015-07-27
    Sponsor Name:Aalborg University Hospital
    Full Title: An Evidence Based, Translational, Cross-Over, Randomized, Double-Blind, Placebo Controlled Study to Evaluate Effectiveness of Topically applied Combination of Diclofenac and Methadone Gel (Diclome...
    Medical condition: Healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10054095 Neuropathic pain LLT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002172-27 Sponsor Protocol Number: NGF0116 Start Date*: 2016-11-09
    Sponsor Name:DOMPé FARMACEUTICI S.P.A.
    Full Title: A 8 weeks, Phase II, single-centre, randomized, double-masked, vehicle-controlled, parallel group study with 4 weeks of follow-up to evaluate preliminary efficacy and safety of recombinant human Ne...
    Medical condition: patients after cataract and refractive surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000385-22 Sponsor Protocol Number: RF-2010-2318561 Start Date*: 2014-10-07
    Sponsor Name:Ospedale San Raffaele di Milano
    Full Title: Nerve Growth Factor eye drops as a novel treatment for vision loss in patients with Retinitis Pigmentosa: from preclinical to clinical Phase II trial.
    Medical condition: Retinitis pigmentosa with cystoid macular edema
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004853 10054467 Macular edema LLT
    17.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004033-13 Sponsor Protocol Number: EMA401-005 Start Date*: 2012-02-06
    Sponsor Name:Spinifex Pharmaceuticals Pty Ltd
    Full Title: A Phase 2 open label biomarker study of angiotensin II type 2 receptor antagonist EMA401 for the treatment of pain in patients with chemotherapy-induced peripheral neuropathy.
    Medical condition: Chemotherapy induced peripheral neuropathy
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004852 10040039 Sensory peripheral neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-000922-12 Sponsor Protocol Number: TV44400-CNS-40083 Start Date*: 2016-01-04
    Sponsor Name:Teva Pharmaceutical Industries, Ltd
    Full Title: A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) Treated with Subcutaneous...
    Medical condition: Relapsing-Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) DE (Completed) IE (Completed) PL (Completed) FI (Completed) ES (Completed) HR (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002143-95 Sponsor Protocol Number: M12-141 Start Date*: 2012-10-04
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-blind, Placebo- and Active-Controlled Study Comparing the Safety and Analgesic Efficacy of ABT-110 to Placebo in Subjects with Chronic Low Back Pain
    Medical condition: Chronic Low Back Pain
    Disease: Version SOC Term Classification Code Term Level
    15.0 10028395 - Musculoskeletal and connective tissue disorders 10008837 Chronic back pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001724-19 Sponsor Protocol Number: CLI-06467AA1-01 Start Date*: 2018-10-04
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A randomised, double-blind, placebo-controlled study to investigate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of CHF6467 after single and repeated ascending doses in su...
    Medical condition: Diabetic Neuropathic Foot Ulcers (DFU) Texas Scale Grade 1A and 2A
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2021-003346-21 Sponsor Protocol Number: NGF0121 Start Date*: 2021-11-24
    Sponsor Name:DOMPé FARMACEUTICI S.P.A.
    Full Title: A 4 week, Phase III, multicenter, double-masked, vehicle-controlled study to evaluate safety and efficacy of Oxervate® (cenegermin) 20 mcg/mL ophthalmic solution versus vehicle, in patients with se...
    Medical condition: Severe Sjogren’s dry eye disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10040766 Sjogren's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003749-39 Sponsor Protocol Number: NGF0221 Start Date*: 2021-12-15
    Sponsor Name:DOMPé FARMACEUTICI S.P.A.
    Full Title: A 4 week, Phase III, multicenter, double-masked, vehicle-controlled study to evaluate safety and efficacy of Cenegermin (Oxervate®) 20 mcg/mL ophthalmic solution versus vehicle, in patients with s...
    Medical condition: Severe Sjogren’s dry eye disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000709-10 Sponsor Protocol Number: UKM12_0026 Start Date*: 2014-12-19
    Sponsor Name:Universitätsklinikum Münster
    Full Title: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002135-15 Sponsor Protocol Number: CMMo/ICTUS/2013 Start Date*: 2014-10-20
    Sponsor Name:Iniciativa Andaluza en Terapias Avanzadas a través de la Fundación Progreso y Salud
    Full Title: Opened phase II controlled and randomized clinical trial to evaluate the efficacy in the intra-arterial infusion with mononuclear autologous bone marrow stem cells in patients with ischemic stroke
    Medical condition: ischemic stroke
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000642-35 Sponsor Protocol Number: HL217-201 Start Date*: 2019-09-19
    Sponsor Name:HANLIM PHARM CO., LTD
    Full Title: A phase IIa randomized, double-blind, multicentre study to evaluate safety and efficacy of HL217 topical ophthalmologic solution in the treatment of exudative Age-Related Macular Degeneration (AMD)
    Medical condition: AMD (age-related macular degeneration)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10068530 Macular degeneration progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017957-37 Sponsor Protocol Number: BAY73-4506/14874 Start Date*: 2010-12-14
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gas...
    Medical condition: Metastatic and /or unresectable gastrointestinal tumors (GIST)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051066 Gastrointestinal stromal tumour PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed) NL (Completed) DE (Completed) GB (Completed) AT (Completed) FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 11:32:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA